Navigation Links
How the Parkin enzyme inhibits neuronal cell death
Date:12/18/2013

Cell biologists at the Ruhr-Universitt Bochum (RUB) have launched a new project to unravel the role of the enzyme Parkin in promoting neuronal survival. The team of Prof Dr Konstanze F. Winklhofer from the Institute of Physiological Chemistry, Department of Molecular Cell Biology, is looking for new therapeutic options to treat Parkinson's disease. The Michael J. Fox Foundation finances this research project with 125,000 US Dollars.

Parkin activates a signal pathway that protects neurons

Parkinson's disease is characterized by the degeneration of neurons that produce the neurotransmitter dopamine. In some cases, mutations in the Parkin gene are the underlying cause of this disease. The RUB researchers have recently discovered that Parkin regulates a signal pathway that protects neurons under cellular stress from damage. When the integrity of mitochondria, the cell's powerhouses, is impaired, Parkin is recruited to a protein complex called LUBAC (linear ubiquitin chain assembly complex) and increases its activity. A signal pathway is then activated that leads to the increased expression of protective factors, thus preventing cell death. The RUB team investigates the molecular mechanism of how parkin activates LUBAC and which other regulators play a role in this process. The goal of the project is to identify novel targets to halt or delay the neurodegenerative process in Parkinson's disease.


'/>"/>
Contact: Dr. Konstanze Winklhofer
konstanze.winklhofer@rub.de
49-234-322-2428
Ruhr-University Bochum
Source:Eurekalert

Page: 1

Related biology news :

1. Investigating the link between Parkinsons and pesticides
2. Genetic mutation increases risk of Parkinsons disease from pesticides
3. Gene-silencing study finds new targets for Parkinsons disease
4. UCLA, Emory researchers find a chemical signature for fast form of Parkinsons
5. Why psychosis is frequently associated with Parkinsons disease?
6. Lasers might be the cure for brain diseases such as Alzheimers and Parkinsons
7. Absence of the SMG1 protein could contribute to Parkinsons and other neurological disorders
8. Rare childhood disease may hold clues to treating Alzheimers and Parkinsons
9. PD map: Putting together the pieces of the Parkinsons puzzle
10. Garvan Institute receives grant to research role of long non-coding RNAs in Parkinsons disease
11. Mild cognitive impairment in Parkinsons disease may be linked with extensive neurodegeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/16/2016)... , Nov. 16, 2016 Sensory ... experience and security for consumer electronics, and ... financial and retail industry, today announced a global ... convenient way to authenticate users of mobile banking ... TrulySecure™ software which requires no specialized ...
(Date:11/15/2016)... Research and Markets has announced the addition of the "Bioinformatics ... ... The global bioinformatics market is projected ... in 2016, growing at a CAGR of 21.1% during the forecast ... by the growing demand for nucleic acid and protein sequencing, increasing ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... From ... innovation is taking over sports. On Thursday, December 15th a panel of entrepreneurs, ... disrupting the playing field at a Smart Talk session. Smart Talk will run ...
(Date:12/8/2016)... USA, and CARDIFF, UK (PRWEB) , ... December ... ... with very high precision light to control cells — optogenetics — is key ... the current state of the art, spatially patterned light projected via free-space optics ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc ... to client demand KbioBox developed a sophisticated “3 click” gene dditing off target ... from KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s ...
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
Breaking Biology Technology: